全文获取类型
收费全文 | 435篇 |
免费 | 53篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 3篇 |
妇产科学 | 2篇 |
基础医学 | 37篇 |
口腔科学 | 4篇 |
临床医学 | 30篇 |
内科学 | 101篇 |
皮肤病学 | 1篇 |
神经病学 | 50篇 |
特种医学 | 19篇 |
外科学 | 60篇 |
综合类 | 15篇 |
预防医学 | 56篇 |
眼科学 | 5篇 |
药学 | 11篇 |
肿瘤学 | 87篇 |
出版年
2019年 | 5篇 |
2018年 | 6篇 |
2017年 | 3篇 |
2016年 | 11篇 |
2015年 | 4篇 |
2014年 | 7篇 |
2013年 | 14篇 |
2012年 | 19篇 |
2011年 | 22篇 |
2010年 | 9篇 |
2009年 | 13篇 |
2008年 | 23篇 |
2007年 | 17篇 |
2006年 | 34篇 |
2005年 | 32篇 |
2004年 | 40篇 |
2003年 | 18篇 |
2002年 | 26篇 |
2001年 | 10篇 |
2000年 | 11篇 |
1999年 | 7篇 |
1997年 | 2篇 |
1994年 | 4篇 |
1993年 | 3篇 |
1992年 | 4篇 |
1991年 | 6篇 |
1990年 | 8篇 |
1989年 | 9篇 |
1988年 | 8篇 |
1987年 | 9篇 |
1986年 | 5篇 |
1985年 | 8篇 |
1984年 | 6篇 |
1983年 | 9篇 |
1982年 | 7篇 |
1981年 | 6篇 |
1980年 | 3篇 |
1979年 | 5篇 |
1978年 | 9篇 |
1976年 | 3篇 |
1975年 | 3篇 |
1974年 | 2篇 |
1973年 | 4篇 |
1972年 | 4篇 |
1971年 | 2篇 |
1970年 | 7篇 |
1968年 | 3篇 |
1967年 | 6篇 |
1965年 | 2篇 |
1962年 | 4篇 |
排序方式: 共有490条查询结果,搜索用时 125 毫秒
441.
William N. William Jr MD Merrill S. Kies MD Frank V. Fossella MD Diane D. Liu PhD Gregory Gladish MD Warner H. Tse RN J. Jack Lee PhD Waun K. Hong MD Scott M. Lippman MD Edward S. Kim MD 《Cancer》2010,116(10):2401-2408
BACKGROUND:
Bevacizumab has recently been demonstrated to prolong overall survival when added to carboplatin and paclitaxel for chemotherapy‐naïve patients with nonsquamous nonsmall‐cell lung cancer (NSCLC). However, the effects of combining bevacizumab with other standard, front‐line, platinum‐based doublets have not been extensively explored. We designed this single treatment arm, phase 2 trial to determine whether the combination of carboplatin, docetaxel, and bevacizumab is tolerable and prolongs progression‐free survival of chemotherapy‐naïve patients with advanced, nonsquamous NSCLC.METHODS:
Forty patients were treated with up to 6 cycles of carboplatin (AUC 6), docetaxel (75 mg/m2), and bevacizumab (15 mg/kg) on Day 1 every 21 days. Patients with an objective response or stable disease received maintenance bevacizumab (15 mg/kg) every 21 days until disease progression. The primary endpoint was median progression‐free survival. Secondary endpoints included safety, response rates, and overall survival.RESULTS:
The median number of chemotherapy and maintenance bevacizumab cycles/patient was 6 and 2, respectively. Grades 3‐5 adverse events included febrile granulocytopenia (10%), infections (13%), bleeding (13%), thrombotic events (13%), hypertension (5%), bowel perforation (5%), and proteinuria (3%). Median progression‐free survival was 7.9 months and median overall survival was 16.5 months. Partial responses were observed in 21 patients (53%), and stable disease ≥6 weeks occurred in another 17 patients (43%), for a disease control rate of 95%.CONCLUSIONS:
Carboplatin, docetaxel, and bevacizumab were feasible and effective for front‐line treatment of advanced, nonsquamous NSCLC. These data provide further evidence that bevacizumab may be used in combination with multiple standard, platinum‐based doublets in this setting. Cancer 2010. © 2010 American Cancer Society. 相似文献442.
443.
444.
445.
Nash JW Barrett TL Kies M Ross MI Sneige N Diwan AH Lazar AJ 《Journal of cutaneous pathology》2007,34(1):49-54
A 44-year-old man was referred for a right chest nodule of 3 months duration. A 'benign' nodule had been excised from this location 8 years prior. On examination, palpable nodes were noted in the right axilla. Radiographic studies were significant only for right axillary lymphadenopathy. Histologically, a nodular dermal proliferation composed of poorly differentiated epithelioid cells in nests and focally forming ducts with pseudopapillary architecture comprised the primary tumor. Features of a clear cell hidradenoma were noted focally. Immunohistochemical (IHC) analysis revealed reactivity for HMW cytokeratins, CK5 and CK7, p53, p63, CEA (focal), androgen receptor, EGFR, estrogen receptor (ER), MUC5AC, and strong/diffuse membranous staining for Her-2/neu. Negative stains included villin, TTF-1, CDX2, S-100 protein, vimentin, gross cystic disease fluid protein 15 (GCDFP-15), mammoglobulin, and MUC2. A wide local excision and axillary node dissection was performed. Metastatic tumor involved nine of 28 nodes. Interphase fluorescence in situ hybridization (FISH) demonstrated chromosomal amplification of the Her-2/neu locus within the tumor and a nodal metastasis. The patient has completed adjuvant and radiotherapy, including trastuzumab, and is asymptomatic. We believe this to be the first demonstration of Her-2/neu amplification in a malignant skin adnexal tumor. In analogy to breast carcinoma, these findings suggest the applicability of trastuzumab for patients with metastatic adnexal carcinomas demonstrating Her-2/neu amplification. 相似文献
446.
447.
Esmaeli B Ahmadi MA Youssef A Diba R Amato M Myers JN Kies M El-Naggar A 《Ophthalmic plastic and reconstructive surgery》2004,20(1):22-26
PURPOSE: To evaluate the outcomes among patients with adenoid cystic carcinoma of the lacrimal gland treated at various stages of their disease at a tertiary care cancer center. METHODS: A retrospective case series of 20 patients with adenoid cystic carcinoma of the lacrimal gland treated at a single institution between 1952 and 2002. Clinical records were available for all 20 patients; histologic sections from 12 of the 20 patients were available for review. Disease-free survival was measured from the completion of treatment; overall survival was measured from the date of initial diagnosis. RESULTS: The study included 6 men and 14 women. The mean age at diagnosis was 39.5 years. The median follow-up time was 34 months (range, 6 to 264 months). The local/regional treatment modalities included exenteration with bone removal and radiation therapy (RT) in 5 patients, exenteration with RT (no bone removal) in 8 patients, exenteration (no RT or bone removal) in 1 patient, exenteration with bone removal (no RT) in 1 patient, local resection with RT in 3 patients, and local resection without RT in 2 patients. Overall, 16 patients had RT as part of their treatment regimen. Seven patients (35%) had local recurrence. Sixteen patients (80%) had distant metastasis during the study period. At the time of this report, 13 (65%) of the patients had died of disease. The median disease-free survival for the entire group was 18 months. Eight patients had a predominantly basaloid histologic pattern. Ten patients had verifiable histologic evidence of perineural invasion. CONCLUSIONS: This study underscores the generally grave prognosis for patients with adenoid cystic carcinoma of the lacrimal gland and the difficulty in making any conclusive recommendations for local therapy for this disease. 相似文献
448.
Rosenthal DI Barker JL El-Naggar AK Glisson BS Kies MS Diaz EM Clayman GL Demonte F Selek U Morrison WH Ang KK Chao KS Garden AS 《Cancer》2004,101(11):2567-2573
BACKGROUND: Sinonasal neuroendocrine tumors are rare malignancies that are represented by a spectrum of histologies, including esthesioneuroblastoma (ENB), sinonasal undifferentiated carcinoma (SNUC), neuroendocrine carcinoma (NEC), and small cell carcinoma (SmCC). The authors reviewed their institutional experience to determine whether sinonasal neuroendocrine tumors of different histologies have distinct clinical characteristics that warrant individualized treatment approaches. METHODS: The authors treated 72 adults with pathologically proven, nonmetastatic, primary sinonasal neuroendocrine tumors from 1982 to 2002. There were 31 patients with ENB, 16 patients with SNUC, 18 patients with NEC, and 7 patients with SmCC. Patients with ENB usually were treated with local therapy alone (surgery and/or radiotherapy); only 3 of 31 patients (9.7%) received treatment (radiation) to regional lymphatics, and only 5 of 31 patients (16.1%) received chemotherapy. In contrast, patients with non-ENB histologies usually received chemotherapy (10 of 16 patients with SNUC, 12 of 18 patients with NEC, and 5 of 7 patients with SmCC), and nonsurgical locoregional therapy was used more frequently (6 of 16 patients with SNUC, 4 of 18 patients with NEC, and 5 of 7 patients with SmCC). RESULTS: The median follow-up for surviving patients was 81.5 months (range, 6-266 months). The Kaplan-Meier estimate of overall survival at 5 years was 93.1% for patients with ENB, 62.5% for patients with SNUC, 64.2% for patients with NEC, and 28.6% for patients with SmCC (P = 0.0029; log-rank test). The local control rate at 5 years also was superior for patients who had ENB (96.2%) compared with patients who had SNUC (78.6%), NEC (72.6%), or SmCC (66.7%) (P = 0.04). The regional failure (RF) rate at 5 years was 8.7% for patients with ENB, 15.6% for patients with SNUC, 12.9% for patients with NEC, and 44.4% for patients with SmCC. Additional late events increased the RF rate for patients with ENB to 31.9% at 10 years. The distant metastasis rate at 5 years was 0.0% for patients with ENB, 25.4% for patients with SNUC, 14.1% for patients with NEC, and 75.0% for patients with SmCC. CONCLUSIONS: This spectrum of malignancies with neuroendocrine features shares a common site of origin within the head and neck, but their natural histories appear to diverge into two main groups: ENB and non-ENB. Patients with ENB had excellent local and distant control rates with local therapy alone. Given the higher rates of systemic failure for patients with SNUC, NEC, and SmCC, the authors favor the use of combined-modality therapy for these patients. 相似文献
449.
450.